SUMMARY TO investigate the possibility that anti-CNS antibodies may play a pathogenic role in a number of neurological and psychiatric disorders, a population study was undertaken. Serum Samples were obtained from a total of 257 adults and were screened against sodium dodecyl sulphate polyacrylamide gel electrophoretic blots of various normal, necropsy-derived adult human brain regions. The incidence of IgG immunoreactive banding in the total sample was 30%. Within the diagnostic groups the incidence of banding was: controls 32%, schizophrenia 28%, mental retardation 279'6, cerebellar ataxia 33%, Parkinson's disease 22%, myasthenia gravis 45% and epilepsy 3 1 %. The differences are not statistically significant. There was no significant difference in the numbers and locations of bands between the various diagnostic groups and the controls. The overall incidence of immunoreactivity corresponding to the high molecular weight subunit of neurofilaments was only 6%, thus not confirming a previously reported incidence of 95%. The similarity between the diagnostic and the control sera suggests that caution should be exerted in interpreting the pathogenic significance of anti-CNS immunoreactive banding on Western blots.
Autoimmune involvement has been demonstrated in neurological illnesses such as myasthenia g r a v i~, ' -~ the Guillain-Barre syndrome5-' and multiple sclerosis (reviewed by Weiner and Hauser'). To investigate the possibility that anti-central nervous system (CNS) antibodies may play a wider pathogenic role in neurological and psychiatric diseases, a population study was undertaken. Serum samples were collected and screened against Western blots of human CNS tissue. Immunoblots have the advantage over tissue sections in that immunoreactivity can be resolved to a finite number of bands whose molecular weights can be determined. Our results are presented in tabular form so that comparisons with other studies will be possible.
Diagnostic groups in which the published literature suggested the presence of anti-CNS antibodies were selected for investigation: myasthenia gravis, cerebellar degenerations, diseases of the basal ganglia and schizophrenia. In myasthenia gravis, the serum antibody response is to the acetylocholine receptor (AChR).2-4 The possibility of anti-CNS antibody activity in myasthenia gravis has been raised in several studies. Kott and Ruleg reported a cellular immune response to myelin basic protein in some myasthenia gravis patients. Antibodies to the AChR have been found in the cerebrospinal fluid (CSF) of some myasthenia gravis patients, suggestive of intrathecal productionlo and CSF oligoclonal immunoglobulin G (IgG) bands have been demonstrated." Also, sera of myasthenia gravis patients contains significantly elevated levels of antibodies to neuroblastoma cells.12 These studies suggest a more generalised neuroimmunological abnormality in myasthenia gravis, not one limited to the neuromuscular junction.
Several lines of investigation have suggested the presence of autoantibodies in cerebellar diseases. Serum and CSF antibodies to cerebellar Purkinje cells have been demonstrated in patients with paraneoplastic cerebellar degenerations. '' -' In the childhood opsoclonus-myoclonus syndrome, circulating antibodies to Purkinje cells are present.16 Anticerebellar antibody activity in other forms of Anti-CNS antibodies in neurological and psychiatric dist cerebellar degeneration has not been extensively studied. Recently, in four cases of familial spinocerebellar degeneration, serum antibodies were detected against cortical neurons, Purkinje cells and dorsal root ganglia. '' In diseases of the basal ganglia, by using immunohistochemical techniques serum antibodies to the caudate nucleus have been demonstrated in Huntington's chorea, Sydenham's chorea" l 9 and Parkinson's disease." Further studies have shown the presence of circulating antibodies to sympathetic ganglion cells in Parkinson's disease patients2' 22 suggestive of an autoimmune process.
Since FesselZ3 postulated an autoimmune basis for schizophrenia, many studies using various immunohistochemical, radioimmunofixation and cytotoxicity techniques have been reported. Although the results are conflicting, there is reason to suspect that anti-CNS antibodies may be present in a subset of schizophrenic patients (reviewed by Knightz4 and DeLisi et alZs).
In the course of collecting serum samples, a number of individuals with mental retardation, epilepsy and other neurological disorders were included. For this study it was necessary to investigate an adequate number of serum samples from healthy individuals since anti-CNS antibody activity is not limited to neurological diseases.' l 4 26
Material and methods
Serum samples were obtained from a total of 257 adults (126 females and 131 males) and stored at -40°C until being used. The majority of samples were collected when routine blood tests were being performed. In all other cases informed consent was obtained. This study was approved by hospital ethics review committees.
The schizophrenia group consisted of chronic schizophrenic patients custodially hospitalised. All were taking neuroleptics. The mentally retarded group consisted of patients custodially hospitalised none of whom had a specific neurological diagnosis. The cerebellar ataxia group consisted of patients with various forms of inherited spinocerebellar degeneration: eight with Friedreich's ataxia, eight with spastic ataxia and two with other forms of ataxia. In both Parkinson's disease and myasthenia gravis categories the patients had long standing illnesses and were being treated with appropriate medications. The epileptic group consisted primarily of patients with other neurological and psychiatric disorders who also had active epilepsy requiring anticonvulsant medication. This included three schizophrenic patients, seven mentally retarded patients and one with Alzheimer's disease. In the study there were also two patients each with personality disorder and dementia of unknown aetiology, and one patient each with depression, drug abuse, Alzheimer's disease, post-traumatic encephalopathy, dystonia musculorum deformans and spasmodic torticollis. The control group consisted of healthy hospital employees undergoing routine hepatitis screening and blood donors. The number of individuals in each diagnostic group are listed in table 1.
Brain samples were obtained at the time of necropsy from three neurologically normal adults who had died from nonneurological causes. The time of necropsy was no later than 24 hours after death. Permission for the necropsy was given by the closest relative. Routine neuropathological examination was normal. The brain samples were stored at -80°C until being used.
Western blots were made by standard techniques." Total homogenates of adult human frontal cortex, basal ganglia (equal volumes of putamen and caudate) and cerebellum were homogenised and boiled for 2min in 2.5% sodium dodecyl sulphate (SDS; w/v), 7% 2-mercaptoethanol (v/v) in TBS (50 mM Tris-HC1,200 mM NaC1, pH 7.4) and the proteins separated as a curtain by polyacrylamide gel electrophoresis (PAGE) through a 5 to 17% acrylamide gradient. The gel loading was 10pg protein/mm track width. The separated polypeptides were electrophoretically transferred to a cellulose nitrate sheet. To detect specific antibody binding 3 mm wide strips from the blot were first incubated 30 min in 10% normal horse serum (NHS) in phosphate buffered saline (PBS; 0.1 M phosphate buffer, 0.15 M NaC1, pH 7.4) to block non-specific binding sites, then overnight in the serum sample diluted 1:100 in 10% NHS. A serum concentration of 1:100 gave optimal visualisation of immunoreactive bands without significant background staining. After two 15 min washes in PBS, the blot strips were incubated for 2 h in horseradish peroxidase conjugated rabbit anti-human IgG (Dako Inc) diluted 1:100 in 10% NHS. Antibody binding was detected by washing the blot twice for 15 min in PBS and then for 15min in O.Smg/ml 4-chloro-1-naphthol-0.01% (v/v) hydrogen peroxide." The apparent molecular weights of antigenic polypeptide bands in kdaltons (K) were estimated from pre-stained molecular weight standards (BRL Inc) which were blotted concomitantly. Control blots in which the serum sample was replaced by 10% NHS revealed no bands. MabN2lO is a murine monoclonal antibody which recognises the 210K subunit of neurofilarnent~.~~ Control blots in which MabN2lO was substituted for the serum, and the second antibody replaced by horseradish peroxidase conjugated rabbit anti-mouse immunoglobulin (Dako Inc) diluted 1: 100 The epilepsy category, marked by an asterisk, consists of 13 individuals with epilepsy 1 I of whom are included in other neuropsychiatric diagnostic groups.
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disease against blots of basal ganglia, and all others, including controls and schizophrenics, against blots of frontal cortex. A number of immunoreactive sera were cross checked against all three blots and were found to give similar results. N o brain region-specific immunoreactivity was identified.
All serum samples were tested at least twice on different blots to calculate the incidence of banding in table 1 and tabulate the identified molecular weights in table 2.
For statistical analysis, chi-square and the Fisher exact probability tests were used.
Results
When tested against Western blots prepared with human frontal cortex, 67 serum samples from the control group of 99 individuals displayed no banding. Of the 32 that did react, 21 had only one reactive band, and the others two or more. The overall incidence of positive banding was 32%. A selection of strips from the same Western blot reacted with sera of thecontrol group are illustrated in fig 1. The apparent molecular weiahts of the identified CNS antigens and the intensity of staining of each individual band varied greatly between serum samples. The majority of control results were as those in strips 9 and 10 of fig 1 with no banding. The apparent molecular weights of all the CNS antigens identified by the sera of the control group are presented in table 2.
The largest single patient group studied was that of schizophrenia with 68 cases. When tested against Western blots made from human frontal cortex, 19 (28%) showed immunoreactive banding. Of those that did, again the majority of I I displayed only one band. A selection of strips from the same Western blot reacted with sera of the schizophrenic group are illustrated in fig2. As in the control group, the identified antigen molecular weights and intensity of staining of each band varied greatly between serum samples. The majority of schizophrenic serum results were as those in strips 9 and 10 of fig 2 with no banding. The apparent molecular weights of all the CNS antigens identified by the sera of the schizophrenic group are presented in table 2.
The overall incidence of immunoreactive banding in each of the diagnostic groups is presented in table 1. The identified CNS antigen apparent molecular weights are summarised in table 2. For the total studied population of 257, the incidence of banding was 30%. In those that had bands 65% had only one band and 35% had multiple bands. The distribution of the number of immunoreactive bands is illustrated in fig 3. The epilepsy category consists of 13 individuals with epilepsy 1 1 of whom are ~ncluded in other neuropsychiatric diagnostic groups. Of the two cases with epilepsy not included in other diagnostic groups, one had a reactive band at ZOK and the other had no band. The immunoblots of the first eight entries in the normal control and schizophrenic categories are illustrated in figs I and 2 respectively.
There was no statistically significant difference in the incidence of banding when the diagnostic groups were compared to each other, to the controls, or to the entire studied population. There was also no statistically significant difference in the incidence of multiple bands when the diagnostic groups were compared with each other, with the controls or with the entire studied population. When the immunoreactive bands were separated into categories by molecular weight (high: greater than 90K; middle: 40K to 90K: low: less than 40K) and the comparative analyses repeated, there again was no statistically significant difference between each diagnostic group, the controls and the entire studied population. There was no single band or set of bands that was characteristic of any diagnostic group.
An increase with age in the proportion of antibodies against the CNS in man has been reported by Ingram Using immunohistochemical techniques, he noted a sharp rise in the incidence of anti-CNS antibodies after the age of 55 years. The incidence of anti-neurofilament serum reactivity has likewise been reported to increase with advancing age, particularly so in those over 70. 26 We did not observe a significant difference in the incidence of banding with advancing age within any studied category. For the total study group, the incidence of banding in the second decade was 33%, third decade 41 %, fourth decade 35%, fifth decade 21°/~, sixth decade 39%, and those over 70, 29%. These results are illustrated as a bar graph in fig4. None of the differences between decades were statistically significant.
We did not notice a significant difference in the incidence of banding within any diagnostic group bethe incidence of reactive bands in males was 34% and females 28%, a difference which is not statistically significant. There was no significant difference in the incidence of banding between males and females in each decade of age.
Since medications can induce immune mediated diseases, perhaps a more significant negative finding was that of no correlation between medication intake tween males and females. For the total study group, and the incidence of banding. Everyone in the epi- leptic group was taking anticonvulsants and everyone in the schizophrenic group was taking neuroleptics. Amongst the side effects of anticonvulsants there are immune mediated ones such as hypersensitivity dermatitis, lymphoma-like lesions, lupus-like manifestations, lymphotoxic autoantibodies, defects in cell-mediated immunity, thyroiditis and myasthenia g r a v i~.~'~~ For the neuroleptics the immune mediated side effects include hypersensitivity dermatitis, agranulocytosis, hemolytic anaemia and t h r o m b~c y t o p e n i a .~~ 34 There was no difference in the incidence of banding between the epileptic, schizophrenic and control groups. No one in any of the diagnostic categories was known to have an immunological primary disease or one induced by medications. N o one was receiving immunosuppressive medications.
In the schizophrenic group five patients had tardive dyskinesia, a presumably non-immune complication of n e u r o l e p t i c~.~~ Of these, three had immunoreactive bands, results which did not differ significantly from the controls. 
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Discussion
For this study we had selected diagnostic groups in which the published literature had suggested the possibility of anti-CNS antibodies. No correlation was found between the incidence and pattern of immunoreactive banding and disease category. The normal controls were indistinguishable from the other groups. There was no single band or set of bands that was characteristic of any diagnostic category.
Overall, 70% of our studied population had no immunoreactive banding. Of those that did, 65% had only one band and the remainder two or more. We did not observe an increase in the incidence of banding with advancing age. as had been suggested in two previous reports using immunohistochemical technique^.^^ 30 There was no statistically significant difference in the incidence of banding between males and females. Also. there was no statistically significant difference between controls and those patient populations taking neuroleptics and anticonvulsants.
